Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shrimp-Derived nanoparticles take on denture fungus

NCT ID NCT07694024

Disease control Sponsor: Kerman University of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study compares a new 1% nanochitosan solution to standard nystatin oral suspension for treating Newton's type II denture stomatitis, a fungal infection causing redness and inflammation under dentures. The trial enrolls 30 complete denture wearers diagnosed by an oral specialist. Researchers measure how well each treatment reduces lesion size, burning sensation, and fungal count, aiming to find a safer, natural alternative.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
1% nanochitosan solution
What this could lead to
If effective, nanochitosan could offer a natural, biocompatible alternative to standard antifungal drugs for treating denture-related mouth inflammation.
What could go wrong
This is a small Phase 2 trial with only 30 participants, so results may not apply broadly. Nanochitosan is still experimental and may not work as well as nystatin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

30 people

The number who actually took part.

Started

Jan 2016

Finished

May 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Complete denture wearers diagnosed with Newton's type II denture stomatitis. * Diagnosis verified by an oral medicine specialist. * No use of antifungal agents, antibiotics, corticosteroids, or medications that reduce salivary flow in the month prior to the study. * Willing to provide written informed consent. Exclusion Criteria: * Patients with Alzheimer's disease. * Patients with diabetes mellitus. * Patients with masticatory muscle disorders. * Patients with immunocompromising diseases. * Patients with psychiatric disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic atrophic candidiasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

candidiasis denture stomatitis oral candidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic atrophic candidiasis Denture stomatitis

Contacts and locations

Locations

  • Faculty of Dentistry, Kerman University of Medical Sciences

    Kerman, Kerman, 7618868345, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.